

## **INTERNAL MEDICINE** Blueprint

For traditional, 10-year Maintenance of Certification (MOC) exam and Longitudinal Knowledge Assessment (LKA°)

# ABIM invites diplomates to help develop the Internal Medicine MOC blueprint

Based on feedback from physicians that MOC assessments should better reflect what they see in practice, in 2015 the American Board of Internal Medicine (ABIM) invited certified general internists to provide ratings of the relative frequency and importance of blueprint topics in practice.

This review process, which resulted in a new MOC exam blueprint, will be used on a periodic basis to inform and update all MOC assessments created by ABIM. No matter what form ABIM's assessments ultimately take, they will need to be informed by front-line clinicians sharing their perspective on what is important to know.

A sample of over 300 physicians, similar to the total invited population of internists in age, time spent in direct patient care, and practice setting, provided the blueprint topic ratings. ABIM used this feedback to update the blueprint for MOC assessments (beginning with the Fall 2015 administration of the traditional, 10-year MOC exam).

To inform how assessment content should be distributed across the major blueprint content categories, ABIM considered the average respondent ratings of topic frequency and importance in each of the content categories. A second source of information was the relative frequency of patient conditions in the content categories, as seen by certified Internists and documented by national health care data (described further under *Content distribution* below).

To determine prioritization of specific exam content within each major medical content category, ABIM used the respondent ratings of topic frequency and importance to set thresholds for these parameters in the exam assembly process (described further under *Detailed content outline* below).

### Purpose of the Internal Medicine MOC Assessments

MOC assessments are designed to evaluate whether a certified internist has maintained competence and currency in the knowledge and judgment required for practice. The MOC assessments emphasizes diagnosis and management of prevalent conditions, particularly in areas where practice has

changed in recent years. As a result of the blueprint review by ABIM diplomates, the assessments place less emphasis on rare conditions and focuses more on situations in which physician intervention can have important consequences for patients. For conditions that are usually managed by other specialists, the focus is on recognition rather than on management.

#### **Assessment format**

The traditional, 10-year MOC exam comprises up to 220 single-best-answer multiple-choice questions, of which approximately 50 are new questions that do not count in the examinee's score. Examinees taking the MOC exam will have access to an external resource (i.e., UpToDate®) for the entire exam.

The LKA for MOC is a five-year cycle in which physicians answer questions on an ongoing basis and receive feedback on how they're performing along the way. More information on how assessments are developed can be found at abim.org/about/exam-information/exam-development.aspx.

Most questions describe clinical scenarios and ask about the work done (that is, tasks performed) by physicians in the course of practice:

- **Diagnosis:** making a diagnosis or identifying an underlying condition
- Testing: ordering tests for diagnosis, staging, or follow-up
- Treatment/Care Decisions: recommending treatment or other patient care
- Risk Assessment/Prognosis/Epidemiology: assessing risk, determining prognosis, and applying principles from epidemiologic studies
- Pathophysiology/Basic Science: understanding the pathophysiology of disease and basic science knowledge applicable to patient care

Reflecting the overall predominance of office-based internal medicine practice, most questions describe patient encounters that take place in outpatient settings; some encounters will occur in hospital or other inpatient settings as most general internists provide patient care in these settings as well.

JANUARY 2025

ABIM is committed to working toward health equity and believes that board-certified physicians should have an understanding of health care disparities. Therefore, health equity content that is clinically important to each discipline will be included in assessments, and the use of gender, race, and ethnicity identifiers will be re-evaluated.

Clinical information presented may include patient photographs, radiographs, electrocardiograms, and other media to illustrate relevant patient findings.

Exam tutorials, including examples of ABIM assessment question format, can be found at abim.org/maintenance-of-certification/exam-information/internal-medicine/exam-tutorial.aspx.

#### **Content distribution**

Listed below are the major medical content categories that define the domain for the Internal Medicine traditional, 10-year MOC exam and LKA. The relative distribution of content is expressed as a percentage of the total assessment. To determine the content distribution, ABIM considered the average respondent ratings of topic frequency and importance

MEDICAL CONTENT CATEGORY	Target %
Allergy and Immunology	2%
Cardiovascular Disease	15%
Dermatology	3%
Endocrinology, Diabetes, and Metabolism	10%
Gastroenterology	10%
Hematology	4%
Infectious Disease	10%
Miscellaneous	1%
Nephrology and Urology	6%
Neurology	4%
Obstetrics and Gynecology	3%
Medical Oncology	6%
Ophthalmology	1%
Otolaryngology and Dental Medicine	1%
Psychiatry	3%
Pulmonary Disease	8%
Rheumatology and Orthopedics	10%
Geriatric Syndromes	3%
Total	100%

To cross-validate these self-reported ratings, ABIM also considered the relative frequency of conditions seen in patients from the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Discharge Survey (NHDS) by a cohort of certified internists. Informed by these data, the Internal Medicine Approval Committee and Internal Medicine Board have established the content category targets.

The Internal Medicine MOC assessments may cover other dimensions of medicine as applicable to the medical content categories, such as critical care medicine, preventive medicine, women's health, clinical epidemiology, ethics, nutrition, palliative and end-of-life care, occupational medicine, patient safety, and substance use disorders.

# How the blueprint ratings are used to assemble the MOC assessments

Blueprint reviewers provided ratings of relative frequency in practice for each of the detailed content topics in the blueprint and provided ratings of the relative importance of the topics for each of the tasks described in *Assessment format* above. In rating importance, reviewers were asked to consider factors such as the following:

- High risk of a significant adverse outcome
- Cost of care and stewardship of resources
- Common errors in diagnosis or management
- Effect on population health
- Effect on quality of life
- When failure to intervene by the physician deprives a patient of significant benefit

Frequency and importance were rated on a three-point scale corresponding to low, medium, or high. The median importance ratings are reflected in the *Detailed content outline* below.

The Internal Medicine Approval Committee and Internal Medicine Board, in partnership with the physician community, have set the following parameters for selecting MOC assessment questions according to the blueprint review ratings:

- At least 75% of questions will address high-importance content (indicated in green)
- No more than 25% of questions will address mediumimportance content (indicated in yellow)
- No questions will address low-importance content (indicated in red)

Independent of the importance and task ratings, no more than 18% of questions will address low-frequency content (indicated by "LF" following the topic description).

JANUARY 2025

**Note:** The same topic may appear in more than one medical content category.


### Detailed Content Outline for the Internal Medicine traditional, 10-year MOC exam and the LKA


— High Importance: At least 75% of questions will address topics and tasks with this designation.

— Medium Importance: No more than 25% of questions will address topics and tasks with this designation.

 Low Importance: No questions will address topics and tasks with this designation.

				1	1
ALLERGY AND IMMUNOLOGY (2% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
ANAPHYLAXIS (<2% of exam)					
General anaphylaxis	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Aspirin idiosyncrasy	.F	×		<b>⊘</b>	×
Stinging insect hypersensitivity	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Desensitization therapy	.F	<b>⊘</b>			<b>⊘</b>
Serum sickness*	$\bigcirc$	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>
ASTHMA (<2% of exam)					
General asthma	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Exercise- and cold-induced asthma	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Allergic bronchopulmonary aspergillosis	.F	<b>⊘</b>		<b>⊘</b>	$\otimes$
Nasal polyps and aspirin sensitivity		<b>⊘</b>			<b>⊘</b>
Occupational asthma		<b>⊘</b>		<b>⊘</b>	<b>⊘</b>
Asthma and pregnancy	.F 🕜	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>
Asthma mimics (including vocal cord dysfunction)	.F	<b>⊘</b>			
RHINITIS, SINUSITIS, CONJUNCTIVITIS	(<2% of exam)				
Allergic rhinitis	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Acute and chronic sinusitis	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Allergic conjunctivitis	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Upper airway cough syndrome	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>







ALLERGY AND IMMUNOLOGY continued (2% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
FOOD ALLERGY (<2% of exam)						
Food allergy		<b>⊘</b>	<b>⊘</b>	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>
URTICARIA AND ANGIOEDEMA (<2% o	of exam)					
Hereditary angioedema	LF		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Drug-induced urticaria and angioedema		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other causes of urticaria and angioedema		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Contrast-related allergy		$\bigcirc$		$\bigcirc$	<b>⊘</b>	<b>⊘</b>
SKIN DISORDERS (<2% of exam)						
Atopic dermatitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Contact dermatitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
DRUG ALLERGY OTHER THAN DRUG-	INDUCE	ED URTICARIA	AND ANGIOED	EMA (<2% of exam)		
Drug allergy other than drug- induced urticaria and angioedema	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	
PRIMARY IMMUNODEFICIENCY DISOR	RDERS	(<2% of exam)				
Primary humoral immunodeficiency*	LF	<b>⊘</b>	<b>⊘</b>	×	×	×
Cellular immunodeficiency other than human immunodeficiency virus (HIV) infection	LF	×	$\bigotimes$	×	×	×
Complement deficiency	LF	<b>⊘</b>	<b>⊘</b>	×	×	×
ALLERGIC COMPLICATIONS OF TRAN	ISFUSIO	ONS (<2% of exa	am)			
Hemolytic transfusion reactions	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Transfusion-related acute lung injury	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Transfusion-related urticaria and anaphylaxis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>	<b>×</b>




Low Importance: No questions will address topics and tasks with this designation.

ALLERGY AND IMMUNOLOGY continued (2% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
AUTOIMMUNE SYSTEMIC DISORDER	RS (INC	LUDING IgG4-RE	ELATED DISOR	DERS) (<2% of exam	n)	
Mastocytosis	LF	<b>×</b>	×	×	×	×
Allergic interstitial nephritis	LF	<b>⊘</b>		<b>⊘</b>	×	<b>⊘</b>
Eosinophilic esophagitis	LF		$\bigotimes$		×	×
Eosinophilic pneumonia	LF		$\bigotimes$	×	×	×
Eosinophilic granulomatosis with polyangiitis	LF		×	<b>×</b>	<b>×</b>	<b>×</b>
Hypersensitivity pneumonitis (extrinsic allergic alveolitis)	LF		<b>⊘</b>		×	×
CARDIOVASCULAR DISEASE (15% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
HYPERTENSION (5% of exam) NOTE: This total includes the Hypertension of	content	listed under <b>Endocr</b>	inology Dishetos	and Matabalian and	d Nove brooks are a sel 111	
TOTE. This total includes the Hypertension (		noted ander <b>Endoor</b>	inology, Diabetes	s, and wetabousm and	nephrology and Ul	rology
Essential hypertension		<b>⊘</b>	W Diabetes	s, and wetabolism and	Nephrology and Ul	Pology
					Wephrology and Ol	
Essential hypertension  Renal (including renal parenchymal	LF	<b>⊗</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Essential hypertension  Renal (including renal parenchymal and renovascular)		<ul><li>∅</li><li>∅</li></ul>	<ul><li>⊘</li><li></li></ul>	<ul><li>✓</li><li>✓</li></ul>	<ul><li>∅</li><li>✓</li></ul>	<ul><li>∅</li><li>✓</li></ul>
Essential hypertension  Renal (including renal parenchymal and renovascular)  Coarctation of the aorta  Hypertensive urgency and		<ul><li>∅</li><li>∅</li></ul>	<ul><li>⊘</li><li></li></ul>	<ul><li>✓</li><li>✓</li></ul>	<ul><li>∅</li><li>✓</li></ul>	<ul><li>∅</li><li>✓</li></ul>
Essential hypertension  Renal (including renal parenchymal and renovascular)  Coarctation of the aorta  Hypertensive urgency and emergency	LF	<ul><li>∅</li><li>∅</li></ul>	<ul><li>⊘</li><li></li></ul>	<ul><li>✓</li><li>✓</li></ul>	<ul><li>∅</li><li>✓</li></ul>	<ul><li>✓</li><li>✓</li><li>✓</li></ul>
Essential hypertension  Renal (including renal parenchymal and renovascular)  Coarctation of the aorta  Hypertensive urgency and emergency  Undifferentiated hypertension	LF	<ul><li>∅</li><li>∅</li></ul>	<ul><li>∅</li><li>∅</li></ul>	<ul><li>✓</li><li>✓</li></ul>	<ul><li>∅</li><li>✓</li></ul>	<ul><li>✓</li><li>✓</li><li>✓</li></ul>
Essential hypertension  Renal (including renal parenchymal and renovascular)  Coarctation of the aorta  Hypertensive urgency and emergency  Undifferentiated hypertension  PERICARDIAL DISEASE (<2% of exam,	LF					
Essential hypertension  Renal (including renal parenchymal and renovascular)  Coarctation of the aorta  Hypertensive urgency and emergency  Undifferentiated hypertension  PERICARDIAL DISEASE (<2% of exam)  Pericarditis  Pericardial effusion	LF ) LF					
Essential hypertension  Renal (including renal parenchymal and renovascular)  Coarctation of the aorta  Hypertensive urgency and emergency  Undifferentiated hypertension  PERICARDIAL DISEASE (<2% of exam, Pericarditis	LF LF LF					
Essential hypertension  Renal (including renal parenchymal and renovascular)  Coarctation of the aorta  Hypertensive urgency and emergency  Undifferentiated hypertension  PERICARDIAL DISEASE (<2% of exam)  Pericarditis  Pericardial effusion  Constrictive pericarditis	LF LF LF					
Essential hypertension  Renal (including renal parenchymal and renovascular)  Coarctation of the aorta  Hypertensive urgency and emergency  Undifferentiated hypertension  PERICARDIAL DISEASE (<2% of exam)  Pericarditis  Pericardial effusion  Constrictive pericarditis	LF LF LF					






CARDIOVASCULAR DISEASE continued (15% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
ISCHEMIC HEART DISEASE continued.	(<2%	% of exam)				
Heart failure from ischemic cardiomyopathy		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Non-cardiac chest pain		$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>
Other ischemic heart disease (coronary artery disease and spasm)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>(</b>	<b>⊘</b>
DYSRHYTHMIAS AND CONDUCTION I	DEFEC	CTS (<2% of exam	1)			
Conduction defects		$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>
Bradyarrhythmias		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Tachyarrhythmias		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other dysrhythmias (cardiac resuscitation)*		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
CONGENITAL HEART DISEASE IN ADL	JLTS (<	<2% of exam)				
Atrial septal defect and patent foramen ovale	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Bicuspid aortic valve	LF				<b>⊘</b>	<b>⊘</b>
Other congenital heart disease (patent ductus arteriosus, ventricular septal defect, pulmonic stenosis)	LF	<b>⊘</b>	$\bigcirc$		<b>⊘</b>	<b>⊘</b>
VALVULAR HEART DISEASE (<2% of ex	kam)					
Aortic stenosis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Aortic regurgitation		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Mitral regurgitation		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Mitral stenosis	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Prosthetic heart valve		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
MYOCARDIAL DISEASE (<2% of exam)						
Heart failure with preserved ejection fraction (HFpEF)		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Myocarditis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hypertrophic cardiomyopathy with and without obstruction	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>




X – Low Importance: No questions will address topics and tasks with this designation.

CARDIOVASCULAR DISEASE continued (15% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
MYOCARDIAL DISEASE (<2% of exam)	)					
Restrictive cardiomyopathy	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Dilated cardiomyopathy	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cor pulmonale		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Undifferentiated myocardial disease*		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
ENDOCARDITIS AND OTHER CARDIO	VASC	ULAR INFECTIO	<b>N</b> (<2% of exam)			
Endocarditis	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Infections of the pericardial space	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
Endocarditis prophylaxis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cardiovascular implantable device infection		<b>(</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
VASCULAR DISEASE (<2% of exam)						
Carotid artery disease		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Aorta		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>✓</b>	<b>⊘</b>
Peripheral arterial disease		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Pulmonary vascular disease		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Venous disease of the lower extremities		<b>②</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Superior vena cava syndrome (not due to cancer)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	$\otimes$	$\otimes$
SYNCOPE (<2% of exam)						
Reflex syncope (vasovagal and situational)		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Orthostatic hypotension		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cardiac syncope (structural and electrical)		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>




X – Low Importance: No questions will address topics and tasks with this designation.

CARDIOVASCULAR DISEASE continued (15% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science		
PREOPERATIVE CONSULTATION (<2% of	exam)						
No testing required	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>		
Testing indicated	<b>⊘</b>	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>		
LIPID DISORDERS (<2% of exam)							
Lipid disorders	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>		
ANTITHROMBOTIC THERAPY IN CARDIO	OVASCULAR DISEA	SE (<2% of exam)					
Antithrombotic therapy in cardiovascular disease	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>		
MISCELLANEOUS CARDIOVASCULAR D	ISEASE (PHYSICAL	EXAMINATION F	INDINGS, MURM	URS) (<2% of exar	n)		
Miscellaneous cardiovascular disease (physical examination Lindings, murmurs)	F	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×		
DERMATOLOGY (3% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science		
DERMATITIS (ECZEMAS) (<2% of exam)							
Atopic dermatitis	<b>⊘</b>	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>		
Contact dermatitis	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>		
Photodermatitis L	F 🗸	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×		
Stasis dermatitis	<b>⊘</b>	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>		
Hand dermatitis							
rianu uennaulis	<b>⊘</b>	<b>(</b>	$\bigcirc$	<b>⊘</b>	×		
Drug eruptions	<b>⊗</b>	<ul><li>✓</li></ul>	<b>⊗</b>	<b>Ø</b>	<b>⊘</b>		
	<b>⊗</b>	_		_	_		
Drug eruptions	F	<b>(</b> )	<b>⊘</b>	<b>(</b> )	<b>⊘</b>		
Drug eruptions  Nummular dermatitis  Exfoliative dermatitis (erythroderma,	F	<ul><li>✓</li><li>⊗</li></ul>	<ul><li>∅</li><li>✓</li></ul>	<ul><li>✓</li><li>⊗</li></ul>	<ul><li>✓</li><li>✓</li></ul>		
Drug eruptions  Nummular dermatitis  Exfoliative dermatitis (erythroderma, not including mycosis fungoides)	F	<ul><li>✓</li><li>⊗</li></ul>	<ul><li>✓</li><li>✓</li></ul>	<ul><li>✓</li><li>✓</li><li>✓</li></ul>	<ul><li>✓</li><li>✓</li><li>✓</li></ul>		
Drug eruptions  Nummular dermatitis  Exfoliative dermatitis (erythroderma, not including mycosis fungoides)  Seborrheic dermatitis	F	<ul><li>✓</li><li>⊗</li></ul>	<ul><li>✓</li><li>✓</li></ul>	<ul><li>✓</li><li>✓</li><li>✓</li></ul>	<ul><li>✓</li><li>✓</li><li>✓</li></ul>		




 Low Importance: No questions will address topics and tasks with this designation.

<b>DERMATOLOGY</b> continued (3% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
VASCULAR DERMATOSES (<2% of exa	ım)					
Erythema multiforme	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Erythema nodosum	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Telangiectasia		<b>(</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Leg ulcers		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
ACNE AND ROSACEA (<2% of exam)						
Acne vulgaris		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Rosacea		<b>⊘</b>	×	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
PAPULOSQUAMOUS DERMATOSES (<	<2% of	exam)				
Psoriasis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Pityriasis rosea	LF	<b>⊘</b>	$\otimes$	<b>⊘</b>	<b>⊘</b>	×
Lichen planus	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
SKIN AND SOFT TISSUE INFECTIONS	(<2% (	of exam)				,
Dermatophytes		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Herpes zoster and varicella		$\bigcirc$	<b>/</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Viral exanthems other than varicella	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Cellulitis, erysipelas, and skin abscess		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Necrotizing soft tissue infections and gas gangrene	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	
Lymphadenitis and lymphangitis	LF					×
Ectoparasites (lice, scabies, and others)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>		×
VESICULOBULLOUS DERMATOSES (<	2% of	exam)				
Pemphigus vulgaris	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Dermatitis herpetiformis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×




 Low Importance: No questions will address topics and tasks with this designation.

DERMATOLOGY continued			T	Risk Assessment/	B-th-ub-side-su/
(3% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Prognosis/ Epidemiology	Pathophysiology/ Basic Science
PIGMENT DISORDERS (<2% of exam)					
Vitiligo and other hypopigmentation disorders	<b>⊘</b>	×	<b>⊘</b>	×	×
Melasma (chloasma)	<b>⊘</b>	×	×	×	×
Acanthosis nigricans LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Xeroderma pigmentosa*	×	×	×	×	×
PHOTOSENSITIVITY DERMATOSES (<2% of	of exam)				
Porphyria cutanea tarda LF	<b>⊘</b>	×	×	×	×
Photodermatitis	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
ALOPECIA (<2% of exam)					
Alopecia	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
NODULES AND TUMORS OF THE SKIN (<	2% of exam)				
Seborrheic keratosis	<b>⊘</b>	$\otimes$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Actinic keratosis	<b>⊘</b>	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>
Warts, corns and skin tags	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	
Squamous cell carcinoma of the skin	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	
Basal cell carcinoma of the skin	<b>⊘</b>	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>
Melanoma and nevi	<b>⊘</b>	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>
Mycosis fungoides LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Other nodules and tumors of the skin (dermatofibroma)*	<b>⊘</b>	×	<b>×</b>	$\otimes$	×
CUTANEOUS MANIFESTATIONS OF NUTR	ITIONAL DEFICIEN	ICIES (<2% of ex	kam)		
Cutaneous manifestations of nutritional deficiencies	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>		×
DISORDERS OF THE NAILS (<2% of exam)					
Disorders of the nails	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×




Low Importance: No questions will address topics and tasks with this designation.


<b>DERMATOLOGY</b> continued (3% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
ENVIRONMENTAL INJURY OF SKIN (<	2% of	exam)				
Frostbite	LF	<b>⊘</b>	×	<b>⊘</b>	<b>⊘</b>	×
Burns	LF	$\bigcirc$		$\bigcirc$	<b>⊘</b>	<b>⊘</b>
PRESSURE INJURIES (<2% of exam)						
Pressure injuries		$\bigcirc$	<b>/</b>	$\bigcirc$	$\bigcirc$	<b>⊘</b>
Dermatologic emergencies*		$\bigcirc$	<b>⊘</b>	<b>Ø</b>	$\bigcirc$	×
ENDOCRINOLOGY, DIABETES, AND METABOLISM (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
ADRENAL DISORDERS (<2% of exam)						
Adrenal hormonal excess	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Adrenal insufficiency	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Adrenal masses and nodules*	LF	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>
THYROID DISORDERS (<2% of exam)						
Hyperthyroidism		$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Hypothyroidism		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Thyroiditis (not Hashimoto or peripartum)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>Ø</b>
Thyroid nodules and thyroid cancer		$\bigcirc$	$\bigcirc$		<b>⊘</b>	<b>⊘</b>
Euthyroid sick syndrome					<b>⊘</b>	<b>⊘</b>
Thyroid storm*		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	$\bigcirc$
Myxedemal coma*		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Thyroid disease in pregnancy, peripartum, or postpartum period*		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
ENDOCRINE CAUSES OF SECONDAR	Y HYF	PERTENSION (2%	of exam)			
Endocrine causes of secondary hypertension*		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>(</b>




 Low Importance: No questions will address topics and tasks with this designation.

ENDOCRINOLOGY, DIABETES,					
AND METABOLISM continued (10% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
LIPID DISORDERS (<2% of exam)					
Hypercholesterolemia	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Hypertriglyceridemia (not including chylomicronemia)	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>(</b>
Chylomicronemia syndrome	LF 🗸	<b>⊘</b>	×	×	×
Diet and hyperlipidemia	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
OVARIAN DISORDERS AND FEMALE R	EPRODUCTIVE HEAL	TH (<2% of exam	)		
Polycystic ovary syndrome	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Premature ovarian failure*	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Female infertility*	<b>⊘</b>	<b>⊘</b>	×	<b>⊘</b>	×
Hormonal therapy (contraception, postmeLnFopausal replacement therapy, abnormal uterine bleeding)*	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
TESTES AND MALE REPRODUCTIVE H	EALTH (<2% of exam)				
Male hypogonadism	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Male infertility	LF 🗸	<b>⊘</b>	×	×	×
Erectile dysfunction	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Gynecomastia*	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	$\bigcirc$	$\bigcirc$
DIABETES MELLITUS (<2% of exam)					
Type 1 diabetes mellitus	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Type 2 diabetes mellitus	⊗	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Diabetes mellitus and pregnancy	LF 🕜	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Complications of diabetes mellitus		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
DISORDERS OF CALCIUM METABOLIS	M AND BONE (<2% of	f exam)			
Hypercalcemia	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hypocalcemia (not including vitamin D deficiency)	LF 🗸	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>(</b>
Hyperphosphatemia	LF 🕜	<b>⊘</b>	<b>⊘</b>	×	×
Hypophosphatemia	LF 🗸	<b>⊘</b>	<b>⊘</b>	×	×






					I	I
ENDOCRINOLOGY, DIABETES, AND METABOLISM continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
DISORDERS OF CALCIUM METABOLI	SM AN	ID BONE continue	ed (<2% of exa	am)		
Paget disease	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Osteoporosis		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Vitamin D deficiency and osteomalacia		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	
Chronic kidney disease-mineral and bone LdFisorder*	LF		<b>(</b>	<b>⊘</b>		<b>⊘</b>
HYPOTHALAMIC DISORDERS (<2% or	f exam)					
Hypothalamic disorders	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
ANTERIOR PITUITARY DISORDERS (<	2% of	exam)				
Pituitary tumors	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hypopituitarism	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
POSTERIOR PITUITARY AND WATER	НОМЕ	OSTASIS (<2% of	exam)			
Hypernatremia		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hyponatremia		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
ENDOCRINE TUMORS AND ENDOCR	INE MA	ANIFESTATIONS	OF TUMORS (<	2% of exam)		
Insulinoma	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
Carcinoid syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	<b>⊘</b>
Other endocrine tumors or manifestation LoFf tumors*	LF		×	$\otimes$	<b>×</b>	<b>×</b>
HYPOGLYCEMIA NOT DUE TO INSUL	NOMA	(<2% of exam)				
Hypoglycemia not due to insulinoma	l	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
POLYGLANDULAR AUTOIMMUNE DIS	ORDE	RS (<2% of exam	)			
Multiple endocrine hypofunction	LF	<b>⊘</b>	<b>⊘</b>	×	×	×



Low Importance: No questions will address topics and tasks with this designation.


GASTROENTEROLOGY (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
ESOPHAGEAL DISEASE (<2% of exal	m)					
Gastroesophageal reflux		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Barrett esophagus		$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>
Esophageal cancer screening	LF	$\bigcirc$	$\bigcirc$		<b>⊘</b>	
Esophageal motility disorders		$\bigcirc$	$\bigcirc$		<b>⊘</b>	
Medication-induced esophageal disorder		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Esophageal diverticula	LF				×	×
Esophageal strictures and webs					<b>⊘</b>	
Gastroesophageal varices		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>
Infectious esophagitis (Candida, herpes simplex virus, cytomegalovirus)	LF	<b>(</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Mallory-Weiss syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other esophageal disease (eosinophilic esophagitis, esophageal rupture)	LF	<b>⊘</b>	×	<b>⊘</b>	×	×
STOMACH AND DUODENAL DISEAS	SE (<2%	of exam)				
Helicobacter pylori infection		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Peptic ulcer disease (other than Helicobacter pylori infection)		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Gastritis and gastropathy		$\bigcirc$	$\bigcirc$	$\bigcirc$		
Non-ulcer dyspepsia		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	
Disorders of gastric emptying		<b>⊘</b>	$\bigcirc$		<b>⊘</b>	
SMALL INTESTINAL DISEASE (<2%	of exam,	)				
Celiac disease	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Bacterial overgrowth syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Short bowel syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Ischemic bowel disease*		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Crohn disease including Crohn colitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>



 Low Importance: No questions will address topics and tasks with this designation.

LF – Low Frequency: No more tha									
GASTROENTEROLOGY continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science			
SMALL INTESTINAL DISEASE continued	d (<2%	of exam)							
Gastroenteritis other than antibiotic colitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Other small intestinal disease (diarrhea [osmotic, post-surgical, bile salt-induced, nocturnal], gastric bypass complications)	LF		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
COLONIC AND ANORECTAL DISEASE	(<2% of	exam)							
Colorectal cancer screening		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	$\bigcirc$	<b>⊘</b>			
Colon polyposis syndrome and other genetic colon cancer syndromes	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>Ø</b>			
Diverticular disease		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Ulcerative colitis		$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>			
Irritable bowel syndrome		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>			
Hemorrhoids and fissures		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>			
Antibiotic colitis		$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>			
Acute appendicitis		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>			
Radiation colitis	LF		<b>⊘</b>			×			
Other colonic and anorectal disease (constipation, fecal incontinence, neutropenic and lymphocytic colitis)	LF	<b>⊘</b>	<b>⊘</b>			<b>×</b>			
PANCREATIC DISEASE (<2% of exam)									
Acute pancreatitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Chronic pancreatitis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Cystic fibrosis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×			
Neuroendocrine tumors of the pancreas	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Infections of the pancreas and pancreatic abscess	LF		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×			
Other pancreatic disease*			×	$\otimes$		×			






GASTROENTEROLOGY continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
BILIARY TRACT DISEASE (<2% of exam	٦)				-	
Cholelithiasis		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>
Cholecystitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Choledocholithiasis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cholangitis	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Primary sclerosing cholangitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Sphincter of Oddi dysfunction*		<b>⊘</b>	×	×	<b>⊘</b>	<b>⊘</b>
LIVER DISEASE (<2% of exam)						
Viral hepatitis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Liver abscess	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Cirrhosis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Drug-induced liver disease other than acetaminophen	LF	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>(</b>
Autoimmune hepatitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Primary biliary cholangitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cholestasis	LF		<b>⊘</b>		<b>⊘</b>	<b>⊘</b>
Wilson disease	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Liver disease in pregnancy	LF		<b>⊘</b>		<b>⊘</b>	×
Hemochromatosis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hepatic vein thrombosis (Budd-Chiari syndrome)	LF				<b>⊘</b>	×
Fatty liver and nonalcoholic steatohepatitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	$\bigcirc$	
Alcoholic hepatitis		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>
Fulminant liver failure	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Gilbert syndrome		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hepatocellular carcinoma screening	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Liver transplantation	LF	$\otimes$	×	<b>(</b>	×	×
Other liver disease*		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>




X – Low Importance: No questions will address topics and tasks with this designation.

GASTROENTEROLOGY continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science			
GASTROINTESTINAL COMPLICATIONS OF HIV INFECTION (<2% of exam)									
Gastrointestinal complications of HIV infection	LF		<b>⊘</b>	<b>⊘</b>	<b>×</b>	<b>×</b>			
GASTROINTESTINAL HEMORRHAGE	GASTROINTESTINAL HEMORRHAGE (<2% of exam)								
Upper gastrointestinal hemorrhage	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Lower gastrointestinal hemorrhage	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Hemorrhage of unknown source*		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
HEMATOLOGY (4% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science			
HYPOPROLIFERATIVE ANEMIA (<2% o	of exar	n)							
Aplastic anemia	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Anemia of chronic disease or organ failure (including kidney failure)		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Iron deficiency anemia		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	$\bigcirc$			
Sideroblastic anemia	LF	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Megaloblastic anemia		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Lead intoxication	LF		<u>/</u>		<b>⊘</b>	×			
HEMOLYTIC ANEMIA (<2% of exam)									
Glucose-6-phosphate dehydrogenase deficiency	LF	<b>⊘</b>	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Autoimmune hemolytic anemia	LF	$\bigcirc$	$\bigcirc$		<b>⊘</b>	<b>⊘</b>			
Microangiopathic hemolytic anemia	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Other hemolytic anemia*		<b>⊘</b>	<b>⊘</b>	×	<b>⊘</b>	×			
HEMOGLOBINOPATHIES AND THALAS	SEM	IAS (<2% of exam)							
Thalassemias		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>			
Hemoglobinopathies		<b>(</b>		<b>⊘</b>	<b>Ø</b>	<b>⊘</b>			




— Low Importance: No questions will address topics and tasks with this designation.


HEMATOLOGY continued (4% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
LEUKOCYTE DISORDERS (<2% of exa	m)					
Acute leukemia	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Chronic leukemia		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Leukocyte disorders (marrow infiltration, myelosuppression, leukopenia, leukocytosis, eosinophilia)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
PLATELET DISORDERS (<2% of exam)						
Idiopathic thrombocytopenic purpura	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Qualitative defects of platelet function (drugs only)		$\bigcirc$	<b>⊘</b>	<b>⊘</b>		<b>⊘</b>
Heparin-induced thrombocytopenia (HIT)	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Essential thrombocythemia	LF		<b>⊘</b>	<b>✓</b>	<b>✓</b>	×
COAGULATION FACTOR DISORDERS	AND 1	THROMBOTIC DI	SORDERS (<2%	of exam)		
Coagulation factor deficiencies	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Primary hypercoagulable states (including antithrombin III [ATIII] deficiency, activated protein C [APC] resistance)	LF	<b>⊗</b>	<b>⊗</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Antiphospholipid antibody syndrome		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Undifferentiated thrombotic disorders*		$\bigotimes$	×	$\otimes$	$\otimes$	<b>×</b>
PORPHYRIAS (<2% of exam)						
Porphyria	LF	<b>⊘</b>	×	×	×	×
MYELOPROLIFERATIVE DISORDERS	(<2% o	of exam)				
Polycythemia vera and other erythrocytosis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Essential thrombocythemia	LF	<b>⊘</b>			<b>⊘</b>	×
Agnogenic myeloid metaplasia and myelofibrosis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	<b>×</b>




Low Importance: No questions will address topics and tasks with this designation.

Li – Low Frequency. No more tr					1	
HEMATOLOGY continued (4% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
MYELODYSPLASTIC SYNDROME (<29	% of ex	kam)				
Myelodysplastic syndrome		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
HEMATOLOGIC MALIGNANCIES (<2%	of exa	am)				
Chronic leukemias		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Acute leukemia	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Non-Hodgkin lymphoma		$\bigcirc$			<b>⊘</b>	<b>⊘</b>
Hodgkin disease	LF				<b>⊘</b>	×
Plasma cell disorder			<b>⊘</b>		<b>⊘</b>	×
TRANSFUSION MEDICINE (PRINCIPLI	ES AN	D COMPLICATIO	NS) (<2% of exa	m)		
Indications for transfusion		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Complications of transfusions	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
HEMATOLOGIC COMPLICATIONS OF	HIV IN	IFECTION (<2% o	f exam)			
Hematologic complications of HIV infection	LF	<b>⊘</b>	<b>⊘</b>		×	×
BONE MARROW TRANSPLANTATION	(LATE	COMPLICATION	<b>S ONLY)</b> (<2% o	f exam)		
Bone marrow transplantation (late complications only)	LF	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
INFECTIOUS DISEASE (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
SKIN AND SOFT TISSUE INFECTIONS	(<2%	of exam)				
Dermatophytes		$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>
Herpes zoster and varicella		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Viral exanthems other than varicella	LF	<b>⊘</b>	×	<b>⊘</b>	<b>⊘</b>	×
Cellulitis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Impetigo	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Necrotizing soft tissue infections and gas gangrene	LF	$\bigcirc$	$\bigcirc$	$\bigcirc$		<b>⊘</b>






INFECTIOUS DISEASE continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
SKIN AND SOFT TISSUE INFECTIONS	<b>S</b> contir	nued (<2% of ex	(am)			
Lymphadenitis and lymphangitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Diabetic foot infections		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Undifferentiated skin and soft tissue infections*		$\bigcirc$	<b>⊘</b>			<b>×</b>
CENTRAL NERVOUS SYSTEM (CNS)	INFEC	TIONS (<2% of ex	ram)			
Meningitis	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Brain abscess	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Encephalitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Epidural abscess	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
latrogenic and postoperative CNS infections	LF	<b>⊘</b>	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>	×
Undifferentiated central nervous system infection*		$\bigcirc$	<b>⊘</b>	<b>⊘</b>		<b>×</b>
UPPER RESPIRATORY TRACT INFEC	TIONS	(<2% of exam)				
Acute and chronic sinusitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Otitis media and externa		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Mastoiditis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>
Common cold		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Pharyngitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Epiglottitis	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Deep infections of head and neck	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other upper respiratory tract infections (pertussis)		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>




Low Importance: No questions will address topics and tasks with this designation.

INFECTIOUS DISEASE continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
EYE INFECTIONS (<2% of exam)						
Preseptal cellulitis	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Conjunctivitis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Keratitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Endophthalmitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Uveitis/Iritis		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Orbital infections	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
LOWER RESPIRATORY TRACT INFEC	CTIONS	(<2% of exam)				
Bronchitis		$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>
Pneumonia		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Lung abscess	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Tuberculosis (TB)	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Infections of the pleural space and empyema	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	
ENDOCARDITIS AND OTHER CARDIO	OVASC	ULAR INFECTION	NS (<2% of exam	n)		
Endocarditis	LF	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>
Infections of the pericardial space	LF	<b>⊘</b>	<b>/</b>	<b>⊘</b>	×	×
Endocarditis prophylaxis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Suppurative thrombophlebitis	LF	<b>⊘</b>	<b>/</b>	<b>⊘</b>	<b>⊘</b>	×
Catheter-related infections		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Device and pocket infections	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
HEPATIC INFECTIONS (<2% of exam)						
Viral hepatitis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Liver abscess	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Cholecystitis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cholangitis	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>




X – Low Importance: No questions will address topics and tasks with this designation.

			1				
INFECTIOUS DISEASE continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science	
ENTERIC INFECTIONS (<2% of exam)							
Esophagitis ( <i>Candida</i> , herpes simplex virus, cytomegalovirus)		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	
Gastroenteritis		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	
Infections of the pancreas and pancreatic abscess	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	
Bacterial peritonitis	LF	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	
Intra-abdominal abscess other than liver and pancreas abscesses	LF	<b>⊘</b>	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>	×	
ACQUIRED IMMUNODEFICIENCY SYN	NDROI	ME (AIDS) AND I	HUMAN IMMUNC	DEFICIENCY VIR	US (HIV) INFECTIO	<b>ON</b> (<2% of exam)	
Transmission and prevention of HIV	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	
Prevention of opportunistic infections	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	
Immune reconstitution inflammatory syndrome (IRIS)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	$\otimes$	×	
Neurologic complications of HIV infection	LF		<b>⊘</b>	<b>⊘</b>	×	<b>×</b>	
Pulmonary complications of HIV infection	LF		<b>⊘</b>	<b>⊘</b>		<b>×</b>	
Gastrointestinal complications of HIV infection	LF		<b>⊘</b>	<b>⊘</b>		×	
Hematologic complications of HIV infection	LF		<b>⊘</b>	<b>⊘</b>	$\bigotimes$	$\otimes$	
Oncologic complications of HIV infection	LF	<b>⊘</b>	<b>⊘</b>	×		$\otimes$	
Rheumatologic complications of HIV infection	LF	×	<b>×</b>	×	$\otimes$	×	
Cardio-metabolic complications of HIV therapy and infection	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	
Oral complications of HIV infection	LF		×	<b>⊘</b>	×	×	




 Low Importance: No questions will address topics and tasks with this designation.

INFECTIOUS DISEASE continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
SEXUALLY TRANSMITTED DISEASES	AND I	NFECTIONS OF	REPRODUCTIVI	E ORGANS (<2% of	exam)	
Urethritis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Genital ulcers	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Vulvovaginitis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Cervicitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Epididymitis	LF	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>	×
Salpingitis and other infections of female pelvis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Syphilis	LF				<b>⊘</b>	<b>⊘</b>
Human papillomavirus and anogenital warts	LF		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	
Undifferentiated sexually transmitted diseases*			<b>⊘</b>	<b>⊘</b>		
URINARY TRACT INFECTIONS (<2% of	of exam	))				
Asymptomatic bacteriuria		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cystitis and pyelonephritis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Perinephric abscess	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
Prostatitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Epididymitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
INFECTIOUS ARTHRITIS (<2% of exam	7)					
Infectious arthritis	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
OSTEOMYELITIS (<2% of exam)						
Osteomyelitis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
BACTEREMIA AND SEPSIS SYNDROM	<b>ME</b> (<2	% of exam)				
Fever and neutropenia		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Systemic inflammatory response syndrome (SIRS) and septic shock		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	
Toxic shock syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Undifferentiated bacteremia and sepsis syndromes*		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>




Low Importance: No questions will address topics and tasks with this designation.

INFECTIOUS DISEASE continued (10% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science				
RHEUMATIC FEVER (<2% of exam)									
Rheumatic fever LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×				
POSTSTREPTOCOCCAL GLOMERULONEPHRITIS (<2% of exam)									
Poststreptococcal glomerulonephritis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>				
PROCEDURE- AND DEVICE-ASSOCIATED	INFECTIONS (<2%	of exam)							
Procedure- and device-associated infections	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>				
NOSOCOMIAL INFECTIONS (<2% of exam)									
Infection control including isolation	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>				
Hospital-acquired infections and prevention	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊗</b>	<b>⊘</b>				
Needlestick injury and postexposure prophylaxis	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>×</b>				
Undifferentiated nosocomial infections*	$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$					
PREVENTION OF INFECTIOUS DISEASE (<	2% of exam)								
Immunization	$\bigcirc$		<b>⊘</b>	$\bigcirc$	<b>⊘</b>				
Infection prevention and control including isolation precautions*	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>				
Needlestick injury and postexposure prophylaxis	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>×</b>				
Travel-related illness prevention*	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	<b>⊘</b>	×				
Other preventions of infectious disease*		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>				
TRAVEL-RELATED ILLNESS (FEVER, RASH	H, DIARRHEA, AND	OTHER) (<2% o	of exam)						
Travel-related illness (fever, rash, diarrhea, and other)*	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>				
INFECTIOUS DISEASE OUTBREAKS (<2%	of exam)								
Infectious disease outbreaks	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>				




Low Importance: No questions will address topics and tasks with this designation.

INFECTIOUS DISEASE continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
SPECIFIC CAUSATIVE ORGANISMS (<2	2% of ∈	exam)				
Viral diseases		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Prion diseases	LF	<b>⊘</b>	×	×	×	×
Rickettsioses and ehrlichioses		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Bacterial diseases	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Chlamydial diseases*	LF	<b>⊘</b>	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>
Mycoplasmal diseases*	LF		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Mycoses (fungal infections)		<b>⊘</b>	<b>⊘</b>		<b>⊘</b>	×
Protozoan and helminthic diseases (including malaria)	LF	<b>⊘</b>	<b>⊘</b>			<b>×</b>
Ectoparasites (including lice and scabies)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>		<b>×</b>
Vector-borne diseases	LF		<b>⊘</b>		<b>⊘</b>	<b>⊘</b>
FEVER OF UNKNOWN ORIGIN (<2% of	exam)					
Fever of unknown origin		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
MISCELLANEOUS (1% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
PRIMARILY EPIDEMIOLOGY (<1% of ex	kam)		'			
Primarily epidemiology	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
PRIMARILY ETHICS (<1% of exam)						
Primarily ethics		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
PRIMARILY SAFETY/QUALITY IMPROV	/EMEN	IT (<1% of exam	)			
Primarily safety and quality improvement	ent	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>




— Low Importance: No questions will address topics and tasks with this designation.

NEPHROLOGY AND UROLOGY (6% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
ACUTE KIDNEY INJURY (<2% of exam	)				•	
Hypotension- or shock-induced acute kidney injury		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Toxic kidney injury		$\bigcirc$	$\bigcirc$		<b>⊘</b>	<b>⊘</b>
Rhabdomyolysis		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>
Hepatorenal syndrome	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Disseminated atheroembolism (cholesterol emboli syndrome)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	$\otimes$
Other acute kidney injury		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Myeloma-induced kidney disease*		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
CHRONIC KIDNEY DISEASE (<2% of e	exam)	'				,
Kidney dialysis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>Ø</b>	<b>⊘</b>
Kidney transplantation	LF	<b>⊘</b>	<b>/</b>	<b>⊘</b>	×	×
Strategies to prevent progression of chronic kidney disease		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Undifferentiated chronic kidney disease*		$\bigcirc$	$\bigcirc$	<b>⊘</b>		
TUBULOINTERSTITIAL DISEASE (<2%	of exa	m)				
Allergic interstitial nephritis	LF	<b>⊘</b>	<b>/</b>	<b>⊘</b>	×	<b>⊘</b>
GLOMERULAR DISORDERS (<2% of e	xam)	'				,
Lupus nephritis and glomerulonephritis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Minimal change disease	LF	$\bigcirc$	$\bigotimes$		×	×
Focal and segmental glomerulosclerosis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	$\otimes$
Membranous nephropathy	LF	<b>⊘</b>	<u>/</u>	<b>⊘</b>	×	×
Membranoproliferative glomerulonephritis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
IgA nephropathy	LF			×	×	×
Anti-glomerular basement membrane syndrome	LF	<b>⊘</b>	<b>⊘</b>	×	×	×




Low Importance: No questions will address topics and tasks with this designation.

NEPHROLOGY AND UROLOGY continued (6% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
GLOMERULAR DISORDERS continued.	(<2% of exam)				
Vasculitis and the kidney	LF 🗸	<b>⊘</b>	<b>⊘</b>	×	×
Other glomerular disorders (post-infectious, hematuria)	<b>⊘</b>	<b>⊘</b>	<b>×</b>	<b>×</b>	×
HYPERTENSION (5% of exam) NOTE: This total includes the Hypertension co	ntent listed under <b>Cardi</b> o	ovascular Disease			
Essential hypertension	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	$\bigcirc$	$\bigcirc$
Primary aldosteronism and mineralocorticoid excess	LF 🕜	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Renovascular hypertension	LF 🗸	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
URINARY TRACT INFECTIONS (<2% of	exam)				
Asymptomatic bacteriuria	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cystitis and pyelonephritis	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>		<b>⊘</b>
Perinephric abscess	LF 🗸	<b>⊘</b>	<b>⊘</b>	×	×
Prostatitis	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Epididymitis	LF 🗸	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
NEPHROLITHIASIS (<2% of exam)					
Nephrolithiasis	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>✓</b>
OTHER KIDNEY DISORDERS (<2% of ex	xam)				
Renal vein thrombosis	LF 🗸	<b>✓</b>	<b>⊘</b>	×	×
Obstructive uropathy (acute or chronic)	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Diabetic nephropathy	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cystic kidney disease (polycystic, medullary sponge, medullary cystic)	LF 🗸	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
UROLOGIC CANCER SCREENING (<2%	of exam)				
Urological cancer screening	LF 🗸	<b>/</b>	<b>✓</b>	<b>✓</b>	×



 Low Importance: No questions will address topics and tasks with this designation.

NEPHROLOGY AND UROLOGY continued (6% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
PROSTATE DISORDERS (<2% of exam	ח)	·			•	
Benign prostatic hyperplasia		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Undifferentiated prostate disorders*		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
OTHER UROLOGIC DISORDERS (<2%	% of exa	am)				
Testicular torsion	LF	$\bigcirc$	$\bigcirc$	<b>✓</b>	<b>⊘</b>	×
Scrotal and testicular nodules and masses other than testicular carcinoma	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Erectile dysfunction		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
URINARY INCONTINENCE (<2% of ex	am)					
Urinary incontinence in women		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>
Urinary incontinence in men		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
WATER AND ELECTROLYTE BALANC	E (<2%	of exam)				
Hypernatremia		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hyponatremia		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hypokalemia		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hyperkalemia		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	$\bigcirc$
Hypercalcemia and hypercalciuria		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hypocalcemia	LF	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hyperphosphatemia	LF				×	×
Hypophosphatemia	LF				×	×
Hypermagnesemia	LF			×	×	×
Hypomagnesemia		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Metabolic acidosis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Metabolic alkalosis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Respiratory acidosis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Respiratory alkalosis	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Mixed acid-base disturbance		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>




 Low Importance: No questions will address topics and tasks with this designation.

				_	
NEPHROLOGY AND UROLOGY continued (6% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
HEMATURIA (<2% of exam)*					
Glomerular cause*	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Non-glomerular cause	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
NEUROLOGY (4% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
SEIZURES (<2% of exam)					
Seizures	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>Ø</b>	<b>⊘</b>
CEREBROVASCULAR DISEASE (WITHOUT S	SPECIFIC DIAGNO	OSIS) (<2% of ex	xam)		
Transient ischemic attack	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Stroke	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cavernous sinus thrombosis LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other cerebrovascular disease (less common anatomic locations, mechanisms)	<b>⊘</b>	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>
HEADACHE AND FACIAL PAIN (<2% of example)	)				
Primary headache	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>✓</b>
Cluster headache	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Secondary headache and facial pain	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
NERVE ROOT SYNDROMES AND MECHANIC	CAL LESIONS OF	THE SPINE (<2	2% of exam)		
Cervical root disease	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Lumbar disc herniation, lumbosacral radiculopathy, sciatica	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Spinal stenosis	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>




X – Low Importance: No questions will address topics and tasks with this designation.

NEUROLOGY continued (4% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
PERIPHERAL NEUROPATHY (<2% of e	xam)					
Acute inflammatory demyelinating polyneuropathy (Guillain-Barre syndrome)	LF	<b>⊘</b>	<b>⊘</b>	<b>Ø</b>	<b>⊘</b>	<b>Ø</b>
Carpal tunnel syndrome and other entrapment neuropathies		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>(</b>
Meralgia paresthetica	LF					<b>⊘</b>
Fibular (peroneal) neuropathy	LF	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Diabetic neuropathy		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Postherpetic neuralgia		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Drugs and toxins	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
CRANIAL NEUROPATHY (<2% of exam	)					
Bell palsy and other facial nerve disorders		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Disorders of eye movement from cranial neuropathy (CN III, IV, VI)	LF		<b>⊘</b>			
Vestibular neuronitis (acute labyrinthitis)	LF		<b>⊘</b>			<b>×</b>
DISORDERS OF CEREBRAL FUNCTIO	N (<2%	% of exam)				
Dementia		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Aphasia		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Medical causes of delirium		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<	<b>⊘</b>
MOVEMENT DISORDERS (<2% of exam	n) '			'	'	'
Parkinson disease and parkinsonism		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Benign essential tremor		$\bigcirc$	<u>/</u>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other movement disorders (including other tremors, dystonias, chorea, myoclonus, tardive dyskinesia, restless leg syndrome)*	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	




Low Importance: No questions will address topics and tasks with this designation.

<b>NEUROLOGY</b> continued (4% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
CENTRAL NERVOUS SYSTEM (CNS) II	NFECT	ΓIONS (<2% of ex	am)			
Meningitis	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Brain abscess	LF	<b>⊘</b>	<b>(</b>	<b>⊘</b>	<b>⊘</b>	×
Encephalitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Epidural abscess	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	×
Neurologic complications of HIV infection	LF		<b>⊘</b>		$\otimes$	$\otimes$
Progressive multifocal leukoencephalopathy*		$\bigcirc$	$\bigcirc$	$\otimes$		$\otimes$
CENTRAL NERVOUS SYSTEM (CNS) T	UMOI	<b>RS</b> (<2% of exam)				
Brain tumors	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Spinal cord tumors and compression	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Carcinomatous meningitis	LF	<b>⊘</b>	<b>⊘</b>	×	×	×
Paraneoplastic neurologic syndromes*	LF	<b>⊘</b>	<b>⊘</b>	×	<b>⊘</b>	×
DISEASES OF MUSCLE AND NEURON	IUSCI	JLAR JUNCTION	(<2% of exam)			
Myasthenia gravis and Lambert-Eaton syndrome	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Polymyositis and dermatomyositis	LF	<b>⊘</b>	<b>⊘</b>	×	×	×
Drug-induced myopathy		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Myotonic dystrophy and other inherited myopathies*		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other diseases of muscle and neuromuscular junction*			<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	
MULTIPLE SCLEROSIS AND OTHER D	EMYE	LINATING DISEA	ASES (<2% of exa	am)		
Multiple sclerosis and other demyelinating diseases		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>




Low Importance: No questions will address topics and tasks with this designation.

NEUROLOGY continued (4% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
OTHER NEUROLOGIC DISORDERS (<	2% of	exam)				
Neurocutaneous syndromes	LF	<b>⊘</b>	×	×	×	×
Head injury		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Spinal cord injury and disorders	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Idiopathic intracranial hypertension	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Motor neuron disease	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>
Neuroleptic malignant syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cerebellar ataxias	LF	<b>⊘</b>	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	×
NEURO-OPHTHALMOLOGY (<2% of e	xam)					
Optic nerve disorders, including optic neuritis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	<b>×</b>
Horner's syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Pupillary abnormalities	LF	<b>⊘</b>	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	<b>⊘</b>
Disorders of eye movement	LF	<b>⊘</b>	×	×	×	×
Papilledema	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
MISCELLANEOUS NEUROLOGIC DISC	ORDE	RS (<2% of exam)				
Vertigo		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>Ø</b>	<b>⊘</b>
Gait and balance disorders		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
OBSTETRICS AND GYNECOLOGY (3% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
DISEASES OF THE VULVA AND EXTER	RNAL	GENITALIA (<2%	of exam)	'		
Diseases of the vulva and external genitalia	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>
BREAST DISORDERS (<2% of exam)						
Breast nodules		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Mastitis and breastfeeding	LF	<b>⊘</b>	<b>/</b>	<b>✓</b>	×	×
Other breast disorders (cyclic pain, nipple discharge)		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×




Low Importance: No questions will address topics and tasks with this designation.

OBSTETRICS AND GYNECOLOGY	,					
continued (3% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
OVARIAN DISORDERS (<2% of exam)					•	
Polycystic ovary syndrome		<b>⊘</b>	<b>/</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Ovarian cysts		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Ovarian cancer	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	×
UTERINE DISORDERS (<2% of exam)						
Uterine fibroids		<b>⊘</b>	<b>/</b>	<b>⊘</b>	<b>⊘</b>	×
Endometriosis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Endometrial cancer	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cervical cancer	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
VAGINAL DISORDERS OTHER THAN	VULVO	VAGINITIS (<2%	of exam)			
Vaginal disorders other than vulvovaginitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
PREGNANCY (<2% of exam)						
Hypertension in pregnancy	LF	<b>⊘</b>	<b>/</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Asthma and pregnancy	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hyperthyroidism during pregnancy or peripartum period	LF		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	
Liver disease in pregnancy	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Peripartum cardiomyopathy	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>		<b>⊘</b>
Ectopic pregnancy	LF	$\bigcirc$	$\bigcirc$			×
Diabetes mellitus and pregnancy		<b>/</b>		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Urinary tract infections in pregnancy		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Nutritional deficiencies*		$\bigcirc$	$\bigcirc$	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>
MENSTRUAL DISORDERS (<2% of exe	am)					
Dysmenorrhea		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Amenorrhea	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Abnormal uterine bleeding		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>




— Low Importance: No questions will address topics and tasks with this designation.


		,	·		1	
OBSTETRICS AND GYNECOLOG continued (3% of exam)	ìΥ	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
MENOPAUSE: MANAGEMENT, RISK	S, AND E	BENEFITS OF TH	IERAPY (<2% of	exam)	'	'
Menopause – management, risks, a benefits of therapy	and	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
FAMILY PLANNING AND REPRODUC	CTIVE HE	EALTH (<2% of ex	xam)			
Family planning and reproductive h	nealth	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	<b>⊘</b>	×
SEXUALLY TRANSMITTED DISEASE	S AND II	NFECTIONS OF	REPRODUCTIVE	E ORGANS (<2% of	exam)	
Sexually transmitted diseases and infections of reproductive organs		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
MEDICAL ONCOLOGY (6% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
LUNG CANCER - CLINICAL PRESEN	NTATION	AND DIAGNOSI	<b>S</b> (<2% of exam)			
Lung cancer (clinical presentation and diagnosis)		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
BREAST CANCER (<2% of exam)						
Breast cancer		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
NEOPLASMS OF THE HEAD AND NE	ECK (<2%	of exam)				
Thyroid nodules and thyroid cance	r	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other neoplasms of the head and r (not thyroid cancer)	neck	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>
GASTROINTESTINAL OR HEPATIC C	CANCER	(<2% of exam)				
Esophageal carcinoma	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>✓</b>
Stomach cancer	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Colorectal cancer		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Pancreatic carcinoma other than pancreatic endocrine tumors	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>		<b>⊘</b>
Hepatocellular carcinoma	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Gallbladder cancer*		$\bigcirc$	$\bigcirc$	<b>×</b>	×	×
Anal cancer*		$\bigcirc$	$\bigcirc$	×	<b>⊘</b>	×




Low Importance: No questions will address topics and tasks with this designation.


MEDICAL ONCOLOGY continued				Treatment/	Risk Assessment/ Prognosis/	Pathophysiology/
(6% of exam)		Diagnosis	Testing	Care Decisions	Epidemiology	Basic Science
UROLOGIC CANCER (<2% of exam)						
Renal cell carcinoma	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Bladder carcinoma	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Prostate carcinoma		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Testicular carcinoma and tumors	LF	$\bigcirc$			<b>⊘</b>	×
GYNECOLOGIC CANCER (<2% of exam	n)					
Ovarian cancer	LF	<b>⊘</b>	$\bigcirc$	<b>✓</b>	<b>⊘</b>	×
Endometrial cancer		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cervical cancer		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Vulvar cancer*		$\bigcirc$	<b>⊘</b>	×	×	×
BONE TUMORS (<2% of exam)						
Bone tumors	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
CENTRAL NERVOUS SYSTEM (CNS) T	UMOF	<b>RS</b> (<2% of exam)				
Brain tumors (primary or metastatic)	LF	<b>⊘</b>	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	×
Spinal cord tumors and compression	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Carcinomatous meningitis	LF	<b>⊘</b>		×	×	×
SKIN CANCER (<2% of exam)						
Squamous cell carcinoma of the skin		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Basal cell carcinoma of the skin		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Melanoma and nevi		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Mycosis fungoides	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
HEMATOLOGIC MALIGNANCIES (<2%	of exa	im)				
Chronic leukemia		<b>⊘</b>	<b>/</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Acute leukemia	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Non-Hodgkin lymphoma	LF	<b>⊘</b>	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	<b>⊘</b>






MEDICAL ONCOLOGY continued (6% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
HEMATOLOGIC MALIGNANCIES conti	nued.	(<2% of exam)				
Hodgkin disease	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Plasma cell disorder	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
SOFT TISSUE CANCER (<2% of exam)						
Soft tissue cancer	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
ONCOLOGIC COMPLICATIONS OF HI	V INF	ECTION (<2% of e	exam)			
Oncologic complications of HIV infection	LF	<b>(</b>	<b>⊘</b>	×	<b>⊘</b>	×
CANCER OF UNKNOWN PRIMARY (<2	2% of	exam)				
Cancer of unknown primary	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
CANCER PREVENTION (<2% of exam)						
Smoking cessation		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Environmental carcinogens		<b>⊘</b>	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>
Inherited cancer risk		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Lifestyle interventions		$\bigcirc$		$\bigcirc$		<b>⊘</b>
ONCOLOGIC EMERGENCIES (<2% of	exam)	)				
Superior vena cava syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Fever and neutropenia		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Brain tumors	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>
Spinal cord tumors and compression	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cardiac tamponade from neoplastic pericarditis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Tumor lysis syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hypercalcemia	LF	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	






MEDICAL ONCOLOGY continued (6% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
COMPLICATIONS OF CANCER AND	ITS TRE	EATMENT (<2% o	f exam)		•	
Pain (including neuropathy)		$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>✓</b>
Dyspnea		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Paraneoplastic syndromes	LF	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Lymphedema*		$\bigcirc$	$\bigcirc$	<b>⊘</b>	×	<b>⊘</b>
Nausea, vomiting, diarrhea, constipation*		$\bigcirc$	<b>(</b>	<b>⊘</b>		<b>⊘</b>
Cardiotoxicity	LF					<b>⊘</b>
Radiation toxicity	LF				<b>⊘</b>	<b>⊘</b>
Immunotherapy*	LF	<b>⊘</b>	$\otimes$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other complications of cancer treatment*	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
CANCER SURVIVORSHIP (<2% of exa	am)					
Surveillance		<b>⊘</b>	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	<b>✓</b>
Second malignancies	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
PSYCHOSOCIAL AND FINANCIAL CO	ONSIDE	RATIONS (<2% o	f exam)			
Psychosocial and financial considerations*		<b>⊘</b>	<b>(</b>	<b>⊘</b>	<b>⊘</b>	×
OPHTHALMOLOGY (1% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
CONJUNCTIVITIS (<1% of exam)						
Viral conjunctivitis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Bacterial conjunctivitis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Allergic conjunctivitis		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other conjunctivitis (keratoconjunctivitis sicca [dry eye] undifferentiated)	, LF	<b>⊘</b>	×	<b>⊘</b>	<b>(X)</b>	<b>×</b>
GLAUCOMA (<1% of exam)						
Glaucoma		<b>/</b>	<b>⊘</b>	<b>✓</b>	/	



Low Importance: No questions will address topics and tasks with this designation.

					1	1
<b>OPHTHALMOLOGY</b> continued (1% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
CATARACTS (<1% of exam)						
Cataracts		<b>⊘</b>	<b>⊘</b>	<b>Ø</b>	<b>⊘</b>	×
DISEASES OF THE CORNEA (<1% of	exam)					
Corneal abrasion	LF	<b>✓</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Keratitis (infections of the cornea)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
NEURO-OPHTHALMOLOGY (<1% of e	exam)					
Optic nerve disorders, including optic neuritis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>×</b>	<b>×</b>
Puppillary abnormalities, including anisocoria	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Disorders of eye movement	LF	<b>⊘</b>	×	×	×	×
Papilledema	LF	$\bigcirc$	$\bigcirc$		<b>⊘</b>	<b>⊘</b>
RETINAL DISEASE (<1% of exam)						
Macular degeneration		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Retinal detachment	LF	$\bigcirc$	✓		<b>⊘</b>	<b>⊘</b>
Diabetic retinopathy		$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	
Amaurosis fugax	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Temporal arteritis	LF	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>
Roth spot*					×	×
UVEITIS (<1% of exam)						
Uveitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
MISCELLANEOUS OPHTHALMOLOG	IC DISC	ORDERS (<1% of	exam)			
Episcleritis and scleritis	LF	$\checkmark$	<b>⊘</b>	<b>⊘</b>	×	×
Preseptal cellulitis	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Endophthalmitis	LF	<b>⊘</b>	<b>⊘</b>	<b>Ø</b>	<b>⊘</b>	×
Orbital infections	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×



 Low Importance: No questions will address topics and tasks with this designation.

OTOLARYNGOLOGY AND DENTA MEDICINE (1% of exam)	L	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
DISORDERS OF THE NOSE AND PAR	ANASA	L SINUSES (<1%	of exam)			
Allergic rhinitis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Acute and chronic sinusitis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Disturbances of taste and smell	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Epistaxis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
DISEASES OF THE EAR (<1% of exam)	)					
Benign paroxysmal positional vertigo		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>
Vestibular neuronitis and acute labyrinthitis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Meniere disease	LF	<b>⊘</b>		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Acoustic neuroma	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Presbycusis and other hearing loss		<b>⊘</b>		<b>⊘</b>	<b>⊘</b>	×
Otitis media and externa		$\bigcirc$		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cholesteatoma	LF	<b>⊘</b>	×	×	×	×
Other disorders of the ear and mastoid*			<b>⊘</b>		×	×
DISEASES OF THE ORAL CAVITY, PH	ARYNX	, AND SALIVARY	GLANDS (<1%	of exam)		
Pharyngitis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Epiglottitis	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Deep infections of head and neck	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Parotid disease	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Diseases of the oral mucosa and the tongue		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>(</b>	8
Other disorders of the oral cavity, pharynx, or salivary glands*		$\bigcirc$	$\bigcirc$	<b>⊘</b>	×	×
DISEASES OF THE LARYNX AND AIR	WAY (<	1% of exam)				
Diseases of the larynx and airway	LF	<b>/</b>	<b>/</b>		<b>/</b>	




Low Importance: No questions will address topics and tasks with this designation.

DOVOLUATOV					Risk Assessment/	
PSYCHIATRY (3% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Prognosis/ Epidemiology	Pathophysiology/ Basic Science
MOOD DISORDERS (<2% of exam)						
Depression and suicide		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Bipolar disorder		<b>Ø</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Other mood disorders (psychogenic erectile dysfunction, premenstrual dysphoric disorder)*		<b>⊘</b>		<b>⊘</b>	<b>⊘</b>	<b>(X)</b>
EATING DISORDERS (NOT INCLUDING	G OBE	SITY) (<2% of exa	m)			
Anorexia nervosa	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Bulimia	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
SUBSTANCE USE DISORDER (<2% of	exam)					
Substance use disorder		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
SCHIZOPHRENIA AND DELUSIONAL	(PARA	NOID) DISORDER	<b>IS</b> (<2% of exam	)		
Complications of drug therapy		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Delusional disorder, somatic type*		$\bigcirc$	<b>/</b>	<b>⊘</b>	<b>⊘</b>	×
ANXIETY DISORDERS (<2% of exam)						
Obsessive-compulsive disorder		<b>⊘</b>	×	<b>⊘</b>	<b>⊘</b>	×
Phobias	LF	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>	<b>Ø</b>	×
Post-traumatic stress disorder				<b>⊘</b>		×
Generalized anxiety disorder		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Panic disorder			<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
SOMATOFORM DISORDERS (<2% of e	exam)					
Somatic symptom disorder		<b>Ø</b>	<b>/</b>	<b>⊘</b>	<b>Ø</b>	×
Hypochondriasis*	LF	<b>⊘</b>	<b>/</b>	<b>⊘</b>	<b>⊘</b>	×
Conversion disorders	LF		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
SEXUAL DISORDERS AND GENDER D	YSPH	IORIA (<2% of exa	m)			
Sexual disorders and Gender Dysphoria	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×




X – Low Importance: No questions will address topics and tasks with this designation.

PSYCHIATRY continued (3% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
SLEEP DISORDERS (<2% of exam)		Diagnosis	lesting	Care Decisions	Lpideimology	Dasic Science
Insomnia		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Narcolepsy*		<b>⊘</b>	<b>×</b>	×	×	×
FACTITIOUS DISORDERS (<2% of exam	7)					
Factitious disorders	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
PERSONALITY DISORDERS (<2% of ex	ram)		1			ı
Personality disorders		<b>⊘</b>			<b>⊘</b>	×
NEUROLEPTIC MALIGNANT DISORDE	:R					
Neuroleptic malignant disorder*		$\bigcirc$	<b>②</b>	<b>⊘</b>	$\bigcirc$	
PULMONARY DISEASE (8% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
OBSTRUCTIVE AIRWAY DISEASE (2.5%	% of exam	)				
General asthma		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Chronic bronchitis and emphysema		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
OCCUPATIONAL AND ENVIRONMENTA	AL LUNG	DISEASE (<2	?% of exam)			
Organic inhalations (hypersensitivity pneumonitis)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Inorganic inhalations (pneumoconiosis)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Occupational asthma		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
High-altitude illness	LF		×	<b>⊘</b>	<b>⊘</b>	×
Carbon monoxide poisoning	LF	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>
RESTRICTIVE LUNG DISEASE OTHER	THAN IN	TERSTITIAL	LUNG AND PLEU	JRAL DISEASE (<2	% of exam)	
Pulmonary complications of obesity		$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Chest wall disorders	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Neuromuscular disorders	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Undifferentiated restrictive lung disease*		<b>(</b>	<b>⊘</b>	<b>⊘</b>	<b>Ø</b>	×




 Low Importance: No questions will address topics and tasks with this designation.

PULMONARY DISEASE continued (8% of exam)	·	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
INTERSTITIAL LUNG DISEASE (<2%	of exam	)				
Idiopathic pulmonary fibrosis		<b>⊘</b>	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	<b>⊘</b>
Sarcoidosis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Radiation pneumonitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Drug-induced interstitial lung disease	LF	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Connective tissue disorders and vasculitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>		<b>⊘</b>
Eosinophilic pneumonia	LF	<b>⊘</b>	×	×	×	×
Anti-glomerular basement membrane syndrome	LF		<b>/</b>	×	$\otimes$	$\bigotimes$
PULMONARY VASCULAR DISEASE	(<2% of 6	exam)				
Pulmonary embolism		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Idiopathic pulmonary arterial hypertension	LF	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Cor pulmonale		$\bigcirc$	$\bigcirc$		<b>⊘</b>	<b>⊘</b>
Superior vena cava syndrome	LF	$\bigcirc$		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hepatopulmonary syndrome	LF				<b>⊘</b>	<b>⊘</b>
PLEURAL DISEASE (<2% of exam)						
Noninfectious pleural effusion		<b>⊘</b>	$\bigcirc$	<b>✓</b>	<b>⊘</b>	<b>⊘</b>
Infections of the pleural space and empyema		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Pneumothorax	LF	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>
LOWER RESPIRATORY TRACT INFE	CTIONS	(<2% of exam)				
Bronchitis		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Pneumonia		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Lung abscess	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Tuberculosis	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Infection of the pleural space and empyema	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>		<b>⊘</b>




X – Low Importance: No questions will address topics and tasks with this designation.

PULMONARY DISEASE continued (8% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
BRONCHIECTASIS (<2% of exam)						
Bronchiectasis		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
CONGENITAL LUNG DISEASE (<2% of	exam)					
Cystic fibrosis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
Alpha-1-antitrypsin deficiency	LF	<b>⊘</b>	<b>⊘</b>	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>
ACUTE RESPIRATORY DISTRESS SYN	IDRON	ME (ARDS) (<2% o	of exam)			
Fat embolism	LF	<b>⊘</b>	<b>/</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Transfusion-related acute lung injury	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Acute respiratory distress syndrome (not including fat embolism)	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>(</b>	<b>⊘</b>
LUNG CANCER (<2% of exam)						
Paraneoplastic syndromes	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Undifferentiated lung cancer		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
SLEEP MEDICINE (<2% of exam)						
Obesity-hypoventilation syndrome		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Obstructive sleep apnea		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Insomnia		$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>
Parasomnia	LF	<b>⊘</b>	<b>⊘</b>	<b>✓</b>	<b>⊘</b>	<b>⊘</b>
MANAGEMENT OF VENTILATORS (<29	% of ex	(am)				
Management of ventilators	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
PULMONARY COMPLICATIONS OF HI	V INFE	ECTION (<2% of e	exam)			
Pulmonary complications of HIV infection	LF	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
EVALUATION OF COMMON PULMONA	ARY SY	YMPTOMS (2.5%	of exam)			
Cough		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Dyspnea		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hemoptysis		$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>




Low Importance: No questions will address topics and tasks with this designation.

			·		I	
PULMONARY DISEASE continued (8% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
SOLITARY PULMONARY NODULE (<2	% of e	exam)				
Solitary pulmonary nodule		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
MISCELLANEOUS PULMONARY DISC	ORDEF	RS (INDICATIONS	FOR SPIROMET	<b>TRY)</b> (<2% of exam)		
Miscellaneous pulmonary disorders (indications for spirometry)	LF	<b>⊘</b>		×	×	×
RHEUMATOLOGY AND ORTHOPEDICS (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
CRYSTAL-INDUCED ARTHROPATHY	<2% c	of exam)				
Gout		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Pseudogout		<b>⊘</b>		$\bigcirc$	<b>⊘</b>	<b>⊘</b>
Hydroxyapatite deposition disease	LF					$\otimes$
REGIONAL MUSCULOSKELETAL SYN	IDROI	MES (<2% of exam	)			
Back pain		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Shoulder syndromes		<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Elbow syndromes		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Wrist and hand syndromes		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Hip and pelvic pain		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Knee syndromes		$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
Foot and ankle syndromes		$\bigcirc$	$\bigcirc$	$\bigcirc$	<b>⊘</b>	
SPONDYLOARTHROPATHIES (<2% of	exam)					
Ankylosing spondylitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Reactive arthritis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Psoriatic arthritis		<b>⊘</b>		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Enteropathic arthritis, arthritis with inflammatory bowel disease	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	<b>⊘</b>
Other spondyloarthropathies	LF	×	×	$\otimes$	×	×



Low Importance: No questions will address topics and tasks with this designation.


RHEUMATOLOGY AND ORTHOPEDICS continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
RHEUMATOID ARTHRITIS (<2% of example)	m)					
General clinical presentation: Skeletal disease*		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Systemic manifestations*	LF	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Adverse effects of antirheumatic drugs		<b>(</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>(</b>
Other rheumatoid arthritis	LF		<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
SYSTEMIC LUPUS ERYTHEMATOSUS	(SLE	) (<2% of exam)				
General clinical presentation*	LF	$\bigcirc$	<b>/</b>	<b>(</b>	<b>⊘</b>	<b>⊘</b>
Specific organ system complications	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Discoid lupus and other cutaneous manifestations	LF		<b>⊘</b>	×	$\otimes$	<b>×</b>
Drug-induced lupus*	LF	<b>⊘</b>	<b>⊘</b>		<b>⊘</b>	×
Other topics in systemic lupus erythematosus	LF		<b>⊘</b>	<b>⊘</b>		
SYSTEMIC SCLEROSIS (<2% of exam)						
Scleroderma, generalized	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
CREST syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
Scleroderma, interstitial lung disease	LF	<b>⊘</b>	<b>⊘</b>	×	×	×
Raynaud phenomenon						<b>⊘</b>
VASCULITIS (<2% of exam)						
Polyarteritis nodosa	LF	<b>⊘</b>	<b>⊘</b>	×	×	×
Eosinophilic granulomatosis with polyangiitis	LF	<b>⊘</b>	×	×	×	×
Leukocytoclastic vasculitis	LF	<b>⊘</b>	<b>⊘</b>	×	×	×
Large-vessel vasculitis	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
ANCA-associated vasculitis	LF		<b>⊘</b>	<b>⊘</b>	×	$\otimes$



X – Low Importance: No questions will address topics and tasks with this designation.

RHEUMATOLOGY AND ORTHOPEDICS continued (10% of exam)		Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
OTHER PRIMARY RHEUMATIC DISO	RDERS	(<2% of exam)				
Dermatomyositis and polymyositis	LF	<b>⊘</b>	<b>⊘</b>	×	×	×
Relapsing polychondritis	LF	×	×	×	×	×
Behcet disease	LF	<b>⊘</b>	×	×	×	×
Rheumatic fever	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Sjogren syndrome	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
Fibromyalgia		<b>⊘</b>	<b>/</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Juvenile rheumatoid arthritis	LF	<b>⊘</b>	×	×	×	×
Adult Still disease	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Marfan and Ehlers-Danlos syndromes	LF		<b>⊘</b>	×	×	×
Scoliosis					<b>⊘</b>	×
Arthropathy of hemochromatosis	LF			×	×	×
INFECTIOUS ARTHRITIS (<2% of exar	n)					
Infectious arthritis	LF	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
METABOLIC AND OTHER BONE DISE	ASE (<	2% of exam)				
Hyperparathyroidism		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Paget disease of bone	LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Avascular necrosis and osteonecrosis	LF	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Osteogenesis imperfecta*		<b>⊘</b>	$\bigotimes$	×	×	×
OSTEOARTHRITIS (<2% of exam)						
Osteoarthritis		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	$\bigcirc$
SPORTS INJURIES AND TRAUMA (<2	% of ex	(am)				
Sport injuries and trauma		$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
CHARCOT-MARIE-TOOTH DISEASE (	<2% of	exam)				
Charcot-Marie-Tooth disease	LF	<b>⊘</b>	×	×	×	×






RHEUMATOLOGY AND ORTHOPEDICS continued (10% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
MIXED CONNECTIVE TISSUE DISEASE (<2%	of exam)				
Mixed connective tissue disease*	$\bigcirc$	$\bigcirc$	<b>Ø</b>	<b>⊘</b>	<b>⊘</b>
SELECT TOPICS IN RHEUMATOLOGY (<2%	of exam)				
Select Topics in Rheumatology* LF	<b>Ø</b>	<b>⊘</b>		<b>⊘</b>	<b>Ø</b>
GERIATRIC SYNDROMES (3% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
PRESSURE INJURIES (<2% of exam)					
Pressure Injuries	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
VENOUS ULCERS AND CHRONIC WOUNDS	(<2% of exam)				
Venous ulcers and chronic wounds	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
END-OF-LIFE AND PALLIATIVE CARE OF TH	E ELDERLY (<2%	of exam)			
End-of-life and palliative care of the elderly	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
ETHICS IN THE ELDERLY (<2% of exam)					
Assessment of decisional capacity and competency; surrogate decision-making in the elderly	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
CONSTIPATION IN THE ELDERLY (<2% of example)	am)				
Constipation in the elderly	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
DISORDERS OF SWALLOWING IN THE ELDE	ERLY (<2% of exa	m)			
Disorders of swallowing in the elderly	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
URINARY TRACT INFECTIONS IN THE ELDE	RLY (<2% of exam	n)			
Urinary tract infections in the elderly	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
INCONTINENCE IN THE ELDERLY (<2% of ex	(am)				
Incontinence in the elderly	$\bigcirc$	<b>/</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>



X – Low Importance: No questions will address topics and tasks with this designation.

GERIATRIC SYNDROMES continued (3% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
DEMENTIA IN THE ELDERLY (<2% of exam)					
Dementia in the elderly	$\bigcirc$	$\bigcirc$	<b>⊘</b>	$\bigcirc$	<b>⊘</b>
DELIRIUM IN THE ELDERLY (<2% of exam)					
Delirium in the elderly	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
DIZZINESS AND VERTIGO IN THE ELDERLY	(<2% of exam)				,
Dizziness and vertigo in the elderly	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>Ø</b>	<b>(</b>
NUTRITION IN THE ELDERLY (<2% of exam)					
Nutrition in the elderly	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>Ø</b>	<b>Ø</b>
OPHTHALMOLOGY IN THE ELDERLY (<2% of	of exam)				,
Cataracts	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
Age-related macular degeneration	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×	×
Ischemic optic nerve or retinal disease other than giant cell arteritis*	<b>⊘</b>	<b>⊘</b>	×	<b>⊘</b>	×
Glaucoma*	$\bigcirc$	$\bigcirc$	×	<b>⊘</b>	×
PSYCHIATRY IN THE ELDERLY (<2% of exam	n)				
Depression in the elderly	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Sleep disorders in the elderly	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Neuropsychological testing of the elderly		<b>⊘</b>			×
HIP FRACTURE IN THE ELDERLY (<2% of ex	ram)				
Hip fracture in the elderly	$\bigcirc$	$\bigcirc$	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
COMMON FOOT PROBLEMS IN THE ELDER	RLY (<2% of exam)				
Common foot problems in the elderly	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
PRINCIPLES OF THE GERIATRIC ASSESSM	ENT (<2% of exan	n)			
Principles of the geriatric assessment	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
REHABILITATION AND THE ELDERLY (<2% of	of exam)		,		•
Rehabilitation and the elderly	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×



Low Importance: No questions will address topics and tasks with this designation.

GERIATRIC SYNDROMES continued (3% of exam)	Diagnosis	Testing	Treatment/ Care Decisions	Risk Assessment/ Prognosis/ Epidemiology	Pathophysiology/ Basic Science
OTHER PRIMARY GERIATRIC TOPICS (<2% of exam)					
Clinical pharmacology and aging	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Epidemiology and aging LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Nursing home care	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Home care	<b>⊘</b>	<b>⊘</b>	$\bigcirc$	<b>⊘</b>	×
Presbycusis and hearing loss in the elderly	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>(</b>	<b>×</b>
Elder mistreatment LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×
Falls	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>
Sexual function in the elderly LF	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	<b>⊘</b>	×